Skip to main content
. 2016 Apr 4;7(19):28096–28111. doi: 10.18632/oncotarget.8581

Figure 9. Effects of lenalidomide and proteasome inhibitor on the different stages of plasma cell differentiation.

Figure 9

A. During plasma cell differentiation, lenalidomide inhibits the generation of prePBs, early PCs and LLPCs but has a moderate inhibitory effect on PBs and LLPCs once generated. B. As shown by Leung-Hagesteijn et al. in multiple myeloma [28], antibody-producing cells (APCs), PBs and PCs, are sensitive to proteasome inhibitor because of their high level of Ig synthesis. Proteasome inhibitor treatment induces endoplasmic reticulum-associated protein degradation (ERAD)-related stress.